Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

被引：15

作者：

Shoukier, Mahran ^{[1
]}

Kubiak, Michal ^{[1
]}

Cortes, Jorge ^{[1
]}

机构：

[1] Augusta Univ, Georgia Canc Ctr, 1410 Laney Walker Rd,CN2222, Augusta, GA 30912 USA

来源：

CURRENT ONCOLOGY REPORTS | 2021年 / 23卷 / 08期

关键词：

Chronic myeloid leukemia; Tyrosine kinase Inhibitors; New generations; Side effects; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC-PHASE; IMATINIB-RESISTANT; SELECTIVE INHIBITOR; FOLLOW-UP; DASATINIB; BOSUTINIB; NILOTINIB; MANAGEMENT; MECHANISMS;

D O I：

10.1007/s11912-021-01087-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review In this review, we analyzed the available data from clinical trials with new tyrosine kinase inhibitors (TKIs) under development and how to consider chronic myeloid leukemia (CML) patients who had either resistance or intolerance to current TKIs for treatment with such agents. Recent Findings Nearly 50% of CML patients treated with TKIs frontline have required a change of therapy by 10 years. Second-line therapy is effective (by achievement of complete cytogenetic response) in only approximately 50% of patients, and available third-generation TKI has been marred by concerns of arterio-occlusive events. These facts highlight the need for additional treatment options. New TKIs have shown promising efficacy and tolerance in CML patients with resistance or intolerance to multiple available TKIs. Additional studies will determine their role in the management of CML.

引用

页数：8

共 37 条

[1]

[Anonymous], Cancer stat facts: leukemia - acute myeloid leukemia 2020

[2]

[Anonymous], PATIENTS TKI RESISTA

[3] BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia [J].

Antelope, Orlando ;

Vellore, Nadeem A. ;

Pomicter, Anthony D. ;

Patel, Ami B. ;

Van Scoyk, Alexandria ;

Clair, Phillip M. ;

Deininger, Michael W. ;

O'Hare, Thomas .

EXPERIMENTAL HEMATOLOGY, 2019, 77 :36-40

[4]

Bose Prithviraj, 2013, Leuk Res Rep, V2, P18

[5] Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease [J].

Branford, Susan ;

Wang, Paul ;

Yeung, David T. ;

Thomson, Daniel ;

Purins, Adrian ;

Wadham, Carol ;

Shahrin, Nur Hezrin ;

Marum, Justine E. ;

Nataren, Nathalie ;

Parker, Wendy T. ;

Geoghegan, Joel ;

Feng, Jinghua ;

Shanmuganathan, Naranie ;

Mueller, Martin C. ;

Dietz, Christian ;

Stangl, Doris ;

Donaldson, Zoe ;

Altamura, Haley ;

Georgievski, Jasmina ;

Braley, Jodi ;

Brown, Anna ;

Hahn, Christopher ;

Walker, Ieuan ;

Kim, Soo-Hyun ;

Choi, Soo-Young ;

Park, Sa-Hee ;

Kim, Dong-Wook ;

White, Deborah L. ;

Yong, Agnes S. M. ;

Ross, David M. ;

Scott, Hamish S. ;

Schreiber, Andreas W. ;

Hughes, Timothy P. .

BLOOD, 2018, 132 (09) :948-961

[6] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias [J].

Cortes, J. E. ;

Kim, D. -W. ;

Pinilla-Ibarz, J. ;

le Coutre, P. ;

Paquette, R. ;

Chuah, C. ;

Nicolini, F. E. ;

Apperley, J. F. ;

Khoury, H. J. ;

Talpaz, M. ;

DiPersio, J. ;

DeAngelo, D. J. ;

Abruzzese, E. ;

Rea, D. ;

Baccarani, M. ;

Mueller, M. C. ;

Gambacorti-Passerini, C. ;

Wong, S. ;

Lustgarten, S. ;

Rivera, V. M. ;

Clackson, T. ;

Turner, C. D. ;

Haluska, F. G. ;

Guilhot, F. ;

Deininger, M. W. ;

Hochhaus, A. ;

Hughes, T. ;

Goldman, J. M. ;

Shah, N. P. ;

Kantarjian, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) :1783-1796

[7]

Cortes J KD-W, 3 PRIOR TKI THERAPIE

[8] Treatment-free remission with first- and second-generation tyrosine kinase inhibitors [J].

Cortes, Jorge ;

Rea, Delphine ;

Lipton, Jeffrey H. .

AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) :346-357

[9] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Pinilla-Ibarz, Javier ;

le Coutre, Philipp D. ;

Paquette, Ronald ;

Chuah, Charles ;

Nicolini, Franck E. ;

Apperley, Jane F. ;

Khoury, H. Jean ;

Talpaz, Moshe ;

DeAngelo, Daniel J. ;

Abruzzese, Elisabetta ;

Rea, Delphine ;

Baccarani, Michele ;

Mueller, Martin C. ;

Gambacorti-Passerini, Carlo ;

Lustgarten, Stephanie ;

Rivera, Victor M. ;

Haluska, Frank G. ;

Guilhot, Francois ;

Deininger, Michael W. ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Shah, Neil P. ;

Kantarjian, Hagop M. .

BLOOD, 2018, 132 (04) :393-404

[10] Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial [J].

Cortes, Jorge E. ;

Gambacorti-Passerini, Carlo ;

Deininger, Michael W. ;

Mauro, Michael J. ;

Chuah, Charles ;

Kim, Dong-Wook ;

Dyagil, Irina ;

Glushko, Nataliia ;

Milojkovic, Dragana ;

le Coutre, Philipp ;

Garcia-Gutierrez, Valentin ;

Reilly, Laurence ;

Jeynes-Ellis, Allison ;

Leip, Eric ;

Bardy-Bouxin, Nathalie ;

Hochhaus, Andreas ;

Brummendorf, Tim H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) :231-+

← 1 2 3 4 →